Primary Results Of The Prospective Single Arm Trial Of Hemodynamic-guided Management Of Heart Failure (GUIDE-HF)

Mandeep R. Mehra
DOI: https://doi.org/10.1016/j.cardfail.2023.10.466
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Background Remotely monitored Hemodynamic-guided management of Heart Failure (HF) has been shown to improve the burden of heart failure hospitalizations (HFH) among patients with moderate (NYHA III) HF recruited for implantation of Pulmonary Artery (PA) Pressure sensors based on prior HFH. Whether moderately symptomatic patients with elevated natriuretic peptides, but no prior HFH benefit from remote hemodynamic-guided management remains uncertain. Trial Design The GUIDE-HF trial portfolio enrolled 2-arms: a first randomized controlled trial arm (active versus sham control), and a second, parallel, active-management, single arm in HF patients regardless of ejection fraction (EF). The GUIDE-HF randomized trial arm has been previously reported (Lancet. 2021; 398:991-1001). The single arm of the trial began concordantly with the randomized trial as an observational study in which HF patients with NYHA class III symptoms with either a previous HFH or elevated natriuretic peptides (but no recent HFH) were implanted with a PA pressure sensor (CardioMEMS, Abbott) and observed for occurrence of the primary composite endpoint of cumulative HF events and mortality at 12 months. This single arm study was primarily designed to test the hypothesis that hemodynamic-guided care leads to similar outcomes in HF patients with successful sensor implantation and either elevated NT-proBNP or BNP only (Group 1) or a recent HFH only (Group 2). The primary hypothesis was to determine equivalence between these groups at the 5% significance level for the primary endpoint at 12 months using a two, one-sided test (TOST) procedure. The initial 2600 patient sample size was estimated to achieve 90% power at the 5% significance level. However, the study was concluded after inclusion of 1359 evaluable patients due to a slower than expected enrollment during the COVID-19 pandemic, and after ascertaining that this sample size retained at least 80% power for the primary analysis. Study Timeline and Outcome Measures The single arm trial achieved data lock on July 17th, 2023, and complete analysis is expected to conclude by September 15th, 2023. Other than the primary outcome measure of equivalence between the elevated natriuretic peptide only and HFH groups, this analysis will secondarily include a) evaluation of benefits in functional capacity and quality of life within and between groups, and b) evaluation of hemodynamic therapeutic effectiveness by comparison of changes in PA pressures and natriuretic peptides over time within and between groups. Additionally, we shall establish the relationship between thresholds of observed benefit based on magnitude of hemodynamic changes with changes in natriuretic peptides, measures of HFH, functional capacity and quality of life. The primary findings of this prospective clinical trial will establish the clinical implications and benefits of remote hemodynamic-guided management in moderately symptomatic HF patients recruited for PA sensor implantation based on elevated natriuretic peptides alone, without a prior HFH. (Clinical Trials NCT03387813)
cardiac & cardiovascular systems
What problem does this paper attempt to address?